SynCore Biotechnology Co (ROCO:4192) Debt-to-Equity : 0.04 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SynCore Biotechnology Co Debt-to-Equity?

SynCore Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$9.61 Mil. SynCore Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$5.39 Mil. SynCore Biotechnology Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was NT$349.21 Mil. SynCore Biotechnology Co's debt to equity for the quarter that ended in Mar. 2024 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for SynCore Biotechnology Co's Debt-to-Equity or its related term are showing as below:

ROCO:4192' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.68
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of SynCore Biotechnology Co was 0.68. The lowest was 0.01. And the median was 0.13.

ROCO:4192's Debt-to-Equity is ranked better than
76.64% of 1070 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:4192: 0.04

SynCore Biotechnology Co Debt-to-Equity Historical Data

The historical data trend for SynCore Biotechnology Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynCore Biotechnology Co Debt-to-Equity Chart

SynCore Biotechnology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.12

0.41

0.28

0.29

0.01

SynCore Biotechnology Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.31	0.34	0.03	0.01	0.04

Competitive Comparison of SynCore Biotechnology Co's Debt-to-Equity

For the Biotechnology subindustry, SynCore Biotechnology Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynCore Biotechnology Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynCore Biotechnology Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where SynCore Biotechnology Co's Debt-to-Equity falls into.

SynCore Biotechnology Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

SynCore Biotechnology Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.114	+	0)	/	357.136
	=	0.01

SynCore Biotechnology Co's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(9.611	+	5.386)	/	349.213
	=	0.04

SynCore Biotechnology Co (ROCO:4192) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

SynCore Biotechnology Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of SynCore Biotechnology Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SynCore Biotechnology Co (ROCO:4192) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynCore Biotechnology Co Ltd (ROCO:4192) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.84 Zhongshan Road, Zhongshan Village, Dongshan Township, Yilan, TWN, 269

Website

https://www.syncorebio.com

SynCore Biotechnology Co Ltd is a biopharmaceutical company. Its pipeline products concentrate on the ophthalmology, oncology, and dermatology fields. The pipeline products of the company include SB01 and 02, SB03, SB04, and SB05. It is engaged in drug development and sale, food advisory, medicine inspection, biotechnology service and intellectual property. It operates in a single industry, the new drug development.

SynCore Biotechnology Co (ROCO:4192) Headlines

No Headlines